Yu Hu

402 total citations
31 papers, 271 citations indexed

About

Yu Hu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Yu Hu has authored 31 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Yu Hu's work include Inflammatory Bowel Disease (6 papers), Pharmacological Effects of Natural Compounds (5 papers) and Mycobacterium research and diagnosis (3 papers). Yu Hu is often cited by papers focused on Inflammatory Bowel Disease (6 papers), Pharmacological Effects of Natural Compounds (5 papers) and Mycobacterium research and diagnosis (3 papers). Yu Hu collaborates with scholars based in China, Hong Kong and Saint Kitts and Nevis. Yu Hu's co-authors include Lingling Zhang, Jingwen Cui, Hongyu Xiang, Qiuhong Xie, Zhen Ye, Linzhen Li, Mingquan Wu, Qiaobo Ye, Yuzheng Li and Maoyi Yang and has published in prestigious journals such as Food Chemistry, European Heart Journal and Molecules.

In The Last Decade

Yu Hu

30 papers receiving 268 citations

Peers

Countries citing papers authored by Yu Hu

Since Specialization

Citations

This map shows the geographic impact of Yu Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Hu more than expected).

Fields of papers citing papers by Yu Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Hu. The network helps show where Yu Hu may publish in the future.

Co-authorship network of co-authors of Yu Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Hu. A scholar is included among the top collaborators of Yu Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Hu. Yu Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Risk Factors and Predictors of Chronic Obstructive Pulmonary Disease in Patients With Obstructive Sleep Apnea–Hypopnea Syndrome at Plateau 2025 ·The Clinical Respiratory Journal ·(unknown), Yu Hu, Bin Li, (unknown), (unknown)	1
2	Predictive value of novel nutritional inflammation indexes in IVIG-unresponsive Kawasaki disease: a retrospective study 2025 ·Frontiers in Nutrition ·(unknown), Dan Xue, Jia Chen, Jun Guo, (unknown), Yu Hu, (unknown)	1
3	Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review 2025 ·Drug Design Development and Therapy ·Wei Shang, Xinhui Li, Lixian Zeng, Zhi Li, Yu Hu, (unknown), Fengjun Cao, (unknown)	1
4	Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy 2024 ·Frontiers in Pharmacology ·(unknown), Zhen Ye, Yu Hu, Mingquan Wu, Liulin Chen, Linzhen Li, (unknown), (unknown), Chen Zhang, Maoyi Yang, (unknown), Qiaobo Ye, (unknown)	6
5	Z-Ligustilide: A Potential Therapeutic Agent for Atherosclerosis Complicating Cerebrovascular Disease 2024 ·Biomolecules ·(unknown), Qianqian Tian, (unknown), (unknown), Yu Hu, (unknown), Zhi Qin, Xinyi Duan, (unknown), (unknown)	3
6	Virtual screening and activity evaluation of human uric acid transporter 1 (hURAT1) inhibitors 2023 ·RSC Advances ·(unknown), Yu Hu, (unknown), Jinbo Yang, (unknown), Peng Wang, Ximing Xu	6
7	Mitochondria in hypoxic pulmonary hypertension, roles and the potential targets 2023 ·Frontiers in Physiology ·(unknown), Yu Hu, Fang Zhang, (unknown), Ri‐Li Ge, Zhenzhong Bai	8
8	Tou Nong powder obstructs ulcerative colitis through the regulation of NF-κB/NLRP3/Caspase-1/GSDMD inflammasome pyroptotic pathway 2023 ·Journal of Ethnopharmacology ·Zhen Ye, Linzhen Li, Yuzheng Li, Yu Hu, Mingquan Wu, Han Yu, (unknown), Chen Zhang, (unknown), Xi Peng, Mengmeng Sun, Kumar Ganesan, (unknown), Qiaobo Ye	14
9	Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease 2023 ·Bioorganic Chemistry ·Wandong Liu, Juan Wang, Suyun Wang, (unknown), Yu Hu, Xiaochun Liu, (unknown), Shengbiao Wan, Ximing Xu	9
10	Major Indole Alkaloids in Evodia Rutaecarpa: The Latest Insights and Review of Their Impact on Gastrointestinal Diseases 2023 ·Biomedicine & Pharmacotherapy ·Liulin Chen, Yu Hu, Zhen Ye, Linzhen Li, (unknown), Mingquan Wu, (unknown), Nan Li, Xudong Wen, Tao Pan, Qiaobo Ye	10
11	The application of Tong-fu therapeutic method on ulcerative colitis: A systematic review and meta-analysis for efficacy and safety of rhubarb-based therapy 2022 ·Frontiers in Pharmacology ·Yuzheng Li, Zhen Ye, Haiqing He, Yu Hu, Mingquan Wu, Linzhen Li, Liulin Chen, (unknown), Qingyu Shi, Chen Zhang, Yu Han, (unknown), (unknown), (unknown), Qiaobo Ye	4
12	A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy 2022 ·Frontiers in Medicine ·Zhen Ye, Qinfeng Huang, (unknown), Yu Hu, Mingquan Wu, (unknown), Linzhen Li, Chuantao Zhang, Xiaohong Zuo, Ailing Wei, Dewen Mao, Qiaobo Ye	5
13	Renshen Baidu powder protects ulcerative colitis via inhibiting the PI3K/Akt/NF-κB signaling pathway 2022 ·Frontiers in Pharmacology ·Zhen Ye, Yuzheng Li, (unknown), Mingquan Wu, Yu Hu, (unknown), Linzhen Li, Han Yu, (unknown), Jin Zhao, (unknown), Qiaobo Ye	14
14	Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis 2022 ·Frontiers in Pharmacology ·Yu Hu, Zhen Ye, (unknown), Linzhen Li, Mingquan Wu, (unknown), Yuzheng Li, Haiqing He, (unknown), Maoyi Yang, (unknown), Qiaobo Ye	16
15	Screening and Evaluation of Flavonoids as Xanthine Oxidase Inhibitors for Reducing Uric Acid through Combined Cell Biology and Molecular Simulation 2021 ·ACS Food Science & Technology ·(unknown), Siyu Zhang, Yidan Zhang, (unknown), (unknown), Juan Wang, Lu Liu, (unknown), (unknown), Yujie Sun, Yu Hu, (unknown), Peng Wang, Rong Li, Ximing Xu	5
16	Nanopore-targeted sequencing for simultaneous diagnosis of suspected sepsis and early targeted therapy 2021 ·Annals of Translational Medicine ·Junying Li, Gaigai Shen, Tiangang Liu, Liang Tang, Linghui Xia, Yu Hu	6
17	A novel fermented soybean, inoculated with selected Bacillus, Lactobacillus and Hansenula strains, showed strong antioxidant and anti-fatigue potential activity 2020 ·Food Chemistry ·Jingwen Cui, (unknown), Lingling Zhang, Yu Hu, Qiuhong Xie, Hongyu Xiang	79
18	The role of deep hypothermic circulatory arrest in surgery for renal or adrenal tumor with vena cava thrombus: a single-institution experience 2018 ·Journal of Cardiothoracic Surgery ·Peng Zhu, (unknown), (unknown), (unknown), Yu Hu, Li Liu, Shaoyi Zheng	7
19	Heavy chain (LvH) and light chain (LvL) of lipovitellin (Lv) of zebrafish can both bind to bacteria and enhance phagocytosis 2016 ·Developmental & Comparative Immunology ·Xue Liang, Yu Hu, (unknown), Shicui Zhang, (unknown), Chen Sun	3
20	Association betweenMTR A2756Gpolymorphism and childhood acute lymphoblastic leukemia: a meta-analysis 2013 ·Leukemia & lymphoma ·Jia Xia, Yadan Wang, Hang Zhang, Yu Hu	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact